Pharma Tips

Novartis delivered growth across all divisions in second quarter

By: Pharma News | Views: 876 | Date: 25-Jul-2013

Group net sales increased 1% (+3% cc) to USD 14.5 billion in the second quarter, with all divisions contributing to growth in constant currencies. Currency had a negative impact of 2 percentage points mainly from the weakening yen. Excluding the impact of patent expiries, underlying sales grew 8% in constant currencies. This performance was fueled by growth products such as Gilenya, Afinitor, Tasigna, Galvus, Xolair, the Q Family and Jakavi, which together contributed USD 4.5 billion or 31% of Group net sal

Novartis delivered growth across all divisions in second quarter

Group net sales increased 1% (+3% cc) to USD 14.5 billion in the second quarter, with all divisions contributing to growth in constant currencies. Currency had a negative impact of 2 percentage points mainly from the weakening yen. Excluding the impact of patent expiries, underlying sales grew 8% in constant currencies. This performance was fueled by growth products such as Gilenya, Afinitor, Tasigna, Galvus, Xolair, the Q Family and Jakavi, which together contributed USD 4.5 billion or 31% of Group net sales, up 13% over the prior-year period. Generics impacted sales by approximately USD 0.8 billion, mainly due to Diovan and Zometa. Sales continued to benefit from the delayed entry of generic competition for Diovan monotherapy in the US.

Pharmaceuticals delivered net sales of USD 8.1 billion (-2%, +1% cc) in the second quarter, driven by strong volume growth (+10 percentage points), which offset the impact of generic competition (USD 0.7 billion, -9 percentage points). Pricing had a negligible impact. Growth products grew 26% (cc) to USD 3.0 billion, contributing 37% of division net sales compared to 30% in the same period last year.

Pharmaceuticals operating income decreased 7% (-3% cc) to USD 2.6 billion. Core operating income was USD 2.5 billion (-10%, -6% cc). Core operating income margin in constant currencies decreased by 2.3 percentage points; currency had a negative impact of 0.6 percentage points, resulting in a net decrease of 2.9 percentage points to 30.4% of net sales, mainly due to the impact of generic competition and continued investments in key projects in Specialty Care and Oncology.

 

Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "Novartis delivered a solid second quarter, resulting in a good first half in 2013. Successful execution on growth brands allowed us to navigate patent expiries and new competition, while deepening our footprint in Emerging Growth Markets like China and Russia. Our underlying business showed strong growth behind significant innovation, with sales up 8% and core operating income up 17% in constant currencies in the first half excluding the impact of generics."

 

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in all these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world.

Previous Page Next Page

People Searching On This Page:
  • muscles
  • q family growth novartis
  • pharmaceutical companies in india

Related Pages


Nearly all UK men survive testicular cancer

Nearly all UK men survive testicular cancer

News | R & D
Date:
19-Aug-2013  Views: 818

Survival for testicular cancer has risen by almost 30% in the last 40 years, with nearly all men now beating the disease, according to figures publish ...
Novartis works in multiple sclerosis (MS) switch

Novartis works in multiple sclerosis (MS) switch

News | Pharma Companies
Date:
22-Jul-2013  Views: 1029

Novartis’ oral MS drug Gilenya has been found to help multiple sclerosis (MS) patients who switch to it after taking standard interferon (interferon b ...
Novartis receives FDA warning

Novartis receives FDA warning

News | FDA
Date:
08-Jul-2013  Views: 873

The FDA has castigated Novartis for what it calls ‘significant violations’ of current good manufacturing practice (CGMP) regulations for finished phar ...
AstraZeneca New global R&D centre & Corporate Headquarters

AstraZeneca New global R&D centre & Corporate Headquarters

News | Pharma Companies
Date:
21-Jun-2013  Views: 1301

AstraZeneca announced that its new UK-based global research and development centre and corporate headquarters will be located at the Cambridge Biomedi ...
Novartis speaks out after second kickbacks lawsuit

Novartis speaks out after second kickbacks lawsuit

News | Pharma Companies
Date:
03-May-2013  Views: 1074

Novartis has expressed its dismay after the US government announced a second lawsuit against the Swiss drug maker in four days, accusing it of paying ...
Post Your Comments (No Login Require)
Name : (required)
Email : (required)
Website :

Comment : (required)

54  + 2 =     
Comments
People Searched About:
Muscles   |   Q Family Growth Novartis   |   Pharmaceutical Companies In India   |  
Google : 74 times | Yahoo : 11 times | Bing : 23 times |